Paul Cernohous

589 total citations
17 papers, 457 citations indexed

About

Paul Cernohous is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Paul Cernohous has authored 17 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pathology and Forensic Medicine and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Paul Cernohous's work include Lymphoma Diagnosis and Treatment (7 papers), Cancer Treatment and Pharmacology (7 papers) and Lung Cancer Treatments and Mutations (5 papers). Paul Cernohous is often cited by papers focused on Lymphoma Diagnosis and Treatment (7 papers), Cancer Treatment and Pharmacology (7 papers) and Lung Cancer Treatments and Mutations (5 papers). Paul Cernohous collaborates with scholars based in United States, France and United Kingdom. Paul Cernohous's co-authors include Martin King, Scott Brun, Barry Bernstein, Eugene Sun, Kai Gu, Ann Hsu, Jennifer L. Moseley, Dale J. Kempf, Jack W. Singer and Ruth Pettengell and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Infectious Diseases.

In The Last Decade

Paul Cernohous

17 papers receiving 436 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Cernohous United States 9 217 179 125 96 95 17 457
Kalpana Bakshi United States 12 88 0.4× 64 0.4× 39 0.3× 58 0.6× 70 0.7× 28 448
Benjamin Tan United States 6 70 0.3× 37 0.2× 138 1.1× 52 0.5× 205 2.2× 9 261
Gudrun Ascherl Germany 7 133 0.6× 46 0.3× 86 0.7× 8 0.1× 314 3.3× 9 433
A. Rueda Spain 10 36 0.2× 17 0.1× 61 0.5× 17 0.2× 102 1.1× 28 303
Johannes Mejer Denmark 10 46 0.2× 29 0.2× 66 0.5× 27 0.3× 179 1.9× 29 397
H. Deicher Germany 10 37 0.2× 18 0.1× 60 0.5× 57 0.6× 53 0.6× 26 336
Sara Nistal Spain 6 42 0.2× 22 0.1× 127 1.0× 57 0.6× 103 1.1× 8 234
J Maral France 10 51 0.2× 105 0.6× 11 0.1× 18 0.2× 101 1.1× 29 344
Nancy Rubin United States 4 190 0.9× 82 0.5× 62 0.5× 61 0.6× 10 0.1× 7 344
Peter Ackerman United States 11 232 1.1× 176 1.0× 27 0.2× 13 0.1× 19 0.2× 30 523

Countries citing papers authored by Paul Cernohous

Since Specialization
Citations

This map shows the geographic impact of Paul Cernohous's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Cernohous with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Cernohous more than expected).

Fields of papers citing papers by Paul Cernohous

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Cernohous. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Cernohous. The network helps show where Paul Cernohous may publish in the future.

Co-authorship network of co-authors of Paul Cernohous

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Cernohous. A scholar is included among the top collaborators of Paul Cernohous based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Cernohous. Paul Cernohous is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
3.
Herbrecht, Raoul, Paul Cernohous, Andreas Engert, et al.. (2013). Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. Annals of Oncology. 24(10). 2618–2623. 36 indexed citations
4.
5.
6.
Borchmann, Peter, Raoul Herbrecht, Martin Wilhelm, et al.. (2011). Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. Leukemia & lymphoma. 52(4). 620–628. 18 indexed citations
7.
Herbrecht, Raoul, David MacDonald, Florian Weißinger, et al.. (2011). CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study. Blood. 118(21). 1605–1605. 2 indexed citations
8.
Pettengell, Ruth, Pier Luigi Zinzani, Geetha Narayanan, et al.. (2010). Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.. Blood. 116(21). 2833–2833. 4 indexed citations
9.
Pettengell, Ruth, Geetha Narayanan, Raghunadharao Digumarti, et al.. (2009). Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology. 27(15_suppl). 8523–8523. 8 indexed citations
10.
11.
Sherman, Kenneth E., Norah J. Shire, Paul Cernohous, et al.. (2005). Liver Injury and Changes in Hepatitis C Virus (HCV) RNA Load Associated with Protease Inhibitor-Based Antiretroviral Therapy for Treatment-Naive HCV-HIV-Coinfected Patients: Lopinavir-Ritonavir versus Nelfinavir. Clinical Infectious Diseases. 41(8). 1186–1195. 22 indexed citations
12.
Benson, Alice, Hedy L. Kindler, A. Hagey, et al.. (2005). Phase 2 study of ABT-751 in patients with refractory metastatic colorectal carcinoma (CRC). Journal of Clinical Oncology. 23(16_suppl). 3537–3537. 6 indexed citations
13.
Hagey, A., Robert A. Figlin, Nancy P. Moldawer, et al.. (2005). Preliminary phase 2 results of ABT-751 in subjects with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology. 23(16_suppl). 4603–4603. 5 indexed citations
14.
Storniolo, A. M., et al.. (2005). Phase 2 results of ABT-751 in subjects with taxane-refractory breast cancer: Interim analysis. Journal of Clinical Oncology. 23(16_suppl). 724–724. 5 indexed citations
15.
Mauer, Ann M., Livia L. Szeto, Robert J. Belt, et al.. (2005). Preliminary results of a phase 2 study of ABT-751 in patients (pts) with taxane-refractory non-small cell lung carcinoma (NSCLC). Journal of Clinical Oncology. 23(16_suppl). 7137–7137. 5 indexed citations
16.
King, Martin, Barry Bernstein, Sharon Walmsley, et al.. (2004). Baseline HIV‐1 RNA Level and CD4 Cell Count Predict Time to Loss of Virologic Response to Nelfinavir, but Not Lopinavir/Ritonavir, in Antiretroviral Therapy–Naive Patients. The Journal of Infectious Diseases. 190(2). 280–284. 28 indexed citations
17.
Kempf, Dale J., Martin King, Barry Bernstein, et al.. (2004). Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine. The Journal of Infectious Diseases. 189(1). 51–60. 172 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kalpana Bakshi Breakdown of academic impact, for papers by Benjamin Tan Breakdown of academic impact, for papers by Gudrun Ascherl Breakdown of academic impact, for papers by A. Rueda Breakdown of academic impact, for papers by Johannes Mejer Breakdown of academic impact, for papers by H. Deicher Breakdown of academic impact, for papers by Sara Nistal Breakdown of academic impact, for papers by J Maral Breakdown of academic impact, for papers by Nancy Rubin Breakdown of academic impact, for papers by Peter Ackerman
Rankless by CCL
2026